30 closest matches · ranked by relevance
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Multiple Myeloma
Primary: Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous…
Multiple Myeloma
Primary: Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC)…
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Progression-free Survival at 18 Months (PFS18) Defined as the Proportion of Patients Alive and Free From Disease Progression at 18 Months From Study Entry — 0.3750…
Multiple Myeloma
Primary: International Myeloma Working Group (IMWG) Response Criteria — 8; 4; 7; 19 participants
Multiple Myeloma
Primary: Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 0; 0; 0 Participants
Relapsed or Refractory Multiple Myeloma
Primary: Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) — 57.7 percentage of participants
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Carfilzomib and Pegylated Liposomal Doxorubicin (Phase I - Part 1). — 56; 30 mg/m^2
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Proportion of Confirmed Tumor Responses Defined to be a Partial Response or Better Noted as the Objective Status on Two Consecutive Evaluations — .4; .25 proportion of…
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Event-free Survival — 29 percentage of participants
Multiple Myeloma
Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Multiple Myeloma
Primary: Overall Survival — 10.0; 10.2 months — p=0.4172
Plasma Cell Leukemia · Plasmacytoma · Recurrent Plasma Cell Myeloma
Primary: Progression Free Survival (PFS) — 38; 24 Participants
Refractory Plasma Cell Myeloma
Primary: Overall Response Rate — 0.35 proportion of participants
Multiple Myeloma
Primary: Best Overall Response Rate (ORR) — 16.7; 23.7 % of participants w/ PR or better
Multiple Myeloma
Primary: Number of Participants With Adverse Events (AEs) — 6 Participants
Multiple Myeloma in Relapse · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bevacizumab and Lenalidomide — 64 percentage of participants
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Proportion of Confirmed Responses With Ixazomib Citrate Alone (Arm A [Closed]), Ixazomib Citrate With Dexamethasone (Arms B + C), or With Dexamethasone and…
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 53; 14; 35 Participants
ISS Stage I Plasma Cell Myeloma · ISS Stage II Plasma Cell Myeloma · ISS Stage III Plasma Cell Myeloma
Primary: Number of Participants With Adverse Events — 8 Participants
Refractory Multiple Myeloma
Primary: Find Maximum Tolerated Dose (MTD) of Bortezomib in Combination With Pomalidomide and Dexamethasone Out to 2.5 Years, by Count of Patients With Dose Limiting Toxicities…
Multiple Myeloma and Plasma Cell Neoplasm
Primary: 6B Antibody Response to Prevnar Vaccine in Peripheral Blood — 3.69; 7.58 fold change
Multiple Myeloma
Primary: The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months — 75 percentage of treated patients
Multiple Myeloma
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 15 percentage of participants
Relapsed or Refractory Multiple Myeloma
Primary: Maximally Tolerated Dose — 40 mg
Recurrent Mantle Cell Lymphoma
Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants
Relapsed and Bortezomib Refractory Multiple Myeloma · Refractory Multiple Myeloma · Multiple Myeloma in Relapse
Primary: Overall Response Rate (PR+nCR+CR) — 34.5 percentage of participants
Multiple Myeloma
Primary: Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response — 0; 0; 3; 11 percentage patients
Multiple Myeloma
Primary: Number of Participants With VGPR or Better Response to Induction — 6 Participants — p=0.597
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: MTD, Defined as the Highest Dose in Which =< 1/6 Patients Experience a Dose-limiting Toxicity, Graded According to the National Cancer Institute Common Terminology…